Logo image of RERE

ATRENEW INC (RERE) Stock Fundamental Analysis

NYSE:RERE - New York Stock Exchange, Inc. - US00138L1089 - ADR - Currency: USD

2.48  +0.03 (+1.22%)

Fundamental Rating

4

Overall RERE gets a fundamental rating of 4 out of 10. We evaluated RERE against 121 industry peers in the Specialty Retail industry. While RERE has a great health rating, there are worries on its profitability. RERE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year RERE has reported negative net income.
In the past 5 years RERE always reported negative net income.
RERE had negative operating cash flow in 4 of the past 5 years.
RERE Yearly Net Income VS EBIT VS OCF VS FCFRERE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -1B -2B

1.2 Ratios

Looking at the Return On Assets, with a value of -2.84%, RERE is doing worse than 66.12% of the companies in the same industry.
With a Return On Equity value of -4.21%, RERE perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
Industry RankSector Rank
ROA -2.84%
ROE -4.21%
ROIC N/A
ROA(3y)-23.13%
ROA(5y)-27.29%
ROE(3y)-29.48%
ROE(5y)-36.06%
ROIC(3y)N/A
ROIC(5y)N/A
RERE Yearly ROA, ROE, ROICRERE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

RERE's Gross Margin of 11.59% is on the low side compared to the rest of the industry. RERE is outperformed by 90.91% of its industry peers.
In the last couple of years the Gross Margin of RERE has grown nicely.
RERE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 11.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.06%
GM growth 5Y28.93%
RERE Yearly Profit, Operating, Gross MarginsRERE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 10 -10 -20 -30 -40

7

2. Health

2.1 Basic Checks

RERE does not have a ROIC to compare to the WACC, probably because it is not profitable.
RERE has less shares outstanding than it did 1 year ago.
The number of shares outstanding for RERE has been increased compared to 5 years ago.
RERE has a worse debt/assets ratio than last year.
RERE Yearly Shares OutstandingRERE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
RERE Yearly Total Debt VS Total AssetsRERE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2B 4B 6B

2.2 Solvency

There is no outstanding debt for RERE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC7.84%
RERE Yearly LT Debt VS Equity VS FCFRERE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 2B 4B 6B

2.3 Liquidity

RERE has a Current Ratio of 2.68. This indicates that RERE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RERE (2.68) is better than 90.91% of its industry peers.
RERE has a Quick Ratio of 2.07. This indicates that RERE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 2.07, RERE belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.07
RERE Yearly Current Assets VS Current LiabilitesRERE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 93.67% over the past year.
RERE shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.37%.
Measured over the past years, RERE shows a very strong growth in Revenue. The Revenue has been growing by 31.79% on average per year.
EPS 1Y (TTM)93.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.13%
Revenue 1Y (TTM)31.37%
Revenue growth 3Y38.71%
Revenue growth 5Y31.79%
Sales Q2Q%29.93%

3.2 Future

RERE is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -18.95% yearly.
Based on estimates for the next years, RERE will show a very strong growth in Revenue. The Revenue will grow by 25.29% on average per year.
EPS Next Y-76.62%
EPS Next 2Y-40.78%
EPS Next 3Y-18.95%
EPS Next 5YN/A
Revenue Next Year24.07%
Revenue Next 2Y25.72%
Revenue Next 3Y25.29%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RERE Yearly Revenue VS EstimatesRERE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 5B 10B 15B 20B 25B
RERE Yearly EPS VS EstimatesRERE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RERE. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 98.14, the valuation of RERE can be described as expensive.
63.64% of the companies in the same industry are cheaper than RERE, based on the Price/Forward Earnings ratio.
RERE's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.49.
Industry RankSector Rank
PE N/A
Fwd PE 98.14
RERE Price Earnings VS Forward Price EarningsRERE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RERE Per share dataRERE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

RERE's earnings are expected to decrease with -18.95% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-40.78%
EPS Next 3Y-18.95%

0

5. Dividend

5.1 Amount

RERE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ATRENEW INC

NYSE:RERE (5/2/2025, 11:03:50 AM)

2.48

+0.03 (+1.22%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)03-11 2025-03-11/amc
Earnings (Next)05-19 2025-05-19
Inst Owners36.15%
Inst Owner Change0.04%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap549.82M
Analysts85.71
Price Target5.1 (105.65%)
Short Float %0.15%
Short Ratio0.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)36.99%
PT rev (3m)58.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 98.14
P/S 0.31
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)0.03
Fwd EY1.02%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.05
BVpS2.3
TBVpS2.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.84%
ROE -4.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 11.59%
FCFM N/A
ROA(3y)-23.13%
ROA(5y)-27.29%
ROE(3y)-29.48%
ROE(5y)-36.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.06%
GM growth 5Y28.93%
F-ScoreN/A
Asset Turnover2.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.68
Quick Ratio 2.07
Altman-Z N/A
F-ScoreN/A
WACC7.84%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.13%
EPS Next Y-76.62%
EPS Next 2Y-40.78%
EPS Next 3Y-18.95%
EPS Next 5YN/A
Revenue 1Y (TTM)31.37%
Revenue growth 3Y38.71%
Revenue growth 5Y31.79%
Sales Q2Q%29.93%
Revenue Next Year24.07%
Revenue Next 2Y25.72%
Revenue Next 3Y25.29%
Revenue Next 5YN/A
EBIT growth 1Y78.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year116.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A